menu
    • menu

    Company profile for Royalty Pharma

    NEW Drugs in Dev: 1
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to paymen...
    Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Royalty PharmaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    110 E 59th Street FL 33 New York, NY 10022
    Telephone
    Telephone
    +1 (212) 883-0200
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.royaltypharma.com/home
    Linkedin
    Linkedin
    https://www.linkedin.com/company/royalty-pharma/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    PBP World Meeting

    Not Confirmed

    envelop Contact Supplier

    PBP World Meeting

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Zymeworks, Royalty Pharma Secure $250M Royalty-Backed Note
    Zymeworks, Royalty Pharma Secure $250M Royalty-Backed Note

    02 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/02/3247161/0/en/Zymeworks-and-Royalty-Pharma-Enter-into-250-Million-Royalty-Backed-Note-Financing.html

    GLOBENEWSWIRE
    02 Mar 2026
    Share Share
    Teva, Royalty Pharma Partner To Fast-Track Vitiligo Treatment
    Teva, Royalty Pharma Partner To Fast-Track Vitiligo Treatment

    11 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/11/3216495/0/en/Teva-and-Royalty-Pharma-Enter-Agreement-to-Accelerate-Development-of-Potential-Treatment-for-Vitiligo.html

    GLOBENEWSWIRE
    11 Jan 2026
    Share Share
    Denali Therapeutics, Royalty Pharma Ink $275M Royalty Deal
    Denali Therapeutics, Royalty Pharma Ink $275M Royalty Deal

    06 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/04/3199643/0/en/Denali-Therapeutics-and-Royalty-Pharma-Announce-275-Million-Royalty-Funding-Agreement.html

    GLOBENEWSWIRE
    06 Dec 2025
    Share Share
    Royalty bestows Zenas with $300M for Autoimmune Approval Push
    Royalty bestows Zenas with $300M for Autoimmune Approval Push

    02 Sep 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/zenas-biopharma-bestowed-300m-royalty-get-autoimmune-asset-across-fda-finish-line

    FIERCE BIOTECH
    02 Sep 2025
    Share Share
    Royalty to pay up to $2B to Revolution Medicines For Cancer Drug
    Royalty to pay up to $2B to Revolution Medicines For Cancer Drug

    25 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/24/3104115/0/en/Royalty-Pharma-and-Revolution-Medicines-Enter-Into-Funding-Agreements-for-Up-to-2-Billion.html

    GLOBENEWSWIRE
    25 Jun 2025
    Share Share
    Biogen taps Royalty for $250M to fund phase 3 lupus
    Biogen taps Royalty for $250M to fund phase 3 lupus

    13 Feb 2025

    // REUTERS

    https://www.fiercebiotech.com/biotech/biogen-enlists-royalty-pursuit-lupus-crown-securing-250m-fund-phase-3-program

    REUTERS
    13 Feb 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search